SMALL CAP MOVERS: Redx Pharma is junior biotech success
Redx Pharma joined the recent spate of junior biotech success stories with an 80 per cent jump to 45p on the back of a licencing deal with AstraZeneca. The FTSE 100 giant will pay $17million to develop Redx’s RXC006 for idiopathic pulmonary fibrosis, where progressive scarring of the lungs is usually fatal. If it makes … Read more